dc.contributor.author | Ramos González, Paula | |
dc.contributor.author | Mato Santos, Susana | |
dc.contributor.author | Chara Ventura, Juan Carlos | |
dc.contributor.author | Verkhratsky, Alexei | |
dc.contributor.author | Matute Almau, Carlos José | |
dc.contributor.author | Cavaliere, Fabio | |
dc.date.accessioned | 2021-04-15T08:33:39Z | |
dc.date.available | 2021-04-15T08:33:39Z | |
dc.date.issued | 2021-03-30 | |
dc.identifier.citation | NPJ Parkinson's Disease 7(1) : (2021) // Article ID 31 | es_ES |
dc.identifier.issn | 2373-8057 | |
dc.identifier.uri | http://hdl.handle.net/10810/50938 | |
dc.description.abstract | The principal hallmark of Parkinson's disease (PD) is the selective neurodegeneration of dopaminergic neurones. Mounting evidence suggests that astrocytes may contribute to dopaminergic neurodegeneration through decreased homoeostatic support and deficient neuroprotection. In this study, we generated induced pluripotent stem cells (iPSC)-derived astrocytes from PD patients with LRRK2(G2019S) mutation and healthy donors of the similar age. In cell lines derived from PD patients, astrocytes were characterised by a significant decrease in S100B and GFAP-positive astrocytic profiles associated with marked decrease in astrocyte complexity. In addition, PD-derived astrocytes demonstrated aberrant mitochondrial morphology, decreased mitochondrial activity and ATP production along with an increase of glycolysis and increased production of reactive oxygen species. Taken together, our data indicate that astrocytic asthenia observed in patient-derived cultures with LRRK2(G2019S) mutation may contribute to neuronal death through decreased homoeostatic support, elevated oxidative stress and failed neuroprotection | es_ES |
dc.description.sponsorship | This work was supported by BIOEF (BIO17/ND/008 to FC), Euskampus, CIBERNED (CB06/0005/0076 to C.M.), the Ministry of Economy and Competitiveness, Government of Spain (SAF2016-75292-R to C.M. and PID2019-109724RB-I00 to C.M.), FEDER and ISCIII (AES 2018-PI18/00513 to S.M.) and the Basque Government (IT1203-19 to C.M.; PIBA19-0059 to S.M.). P.R.G. was supported by a fellowship from the Basque Government | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer | es_ES |
dc.relation | info:eu-repo/grantAgreement/MICINN/SAF2016-75292-R | es_ES |
dc.relation | info:eu-repo/grantAgreement/MICINN/PID2019-109724RB-I00 | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | Parkinson's disease | es_ES |
dc.subject | selective neurodegeneration | es_ES |
dc.subject | dopaminergic neurones | es_ES |
dc.subject | astrocytes | es_ES |
dc.subject | decreased homoeostatic support | es_ES |
dc.subject | deficient neuroprotection | es_ES |
dc.subject | pluripotent stem cells | es_ES |
dc.subject | aberrant mitochondrial morphology | es_ES |
dc.subject | astrocytic asthenia | es_ES |
dc.subject | neuronal death | es_ES |
dc.title | Astrocytic Atrophy as a Pathological Feature of Parkinson's Disease with LRRK2 Mutation | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://www.nature.com/articles/s41531-021-00175-w | es_ES |
dc.identifier.doi | 10.1038/s41531-021-00175-w | |
dc.departamentoes | Neurociencias | es_ES |
dc.departamentoeu | Neurozientziak | es_ES |